Skip to main content
. 2020 Aug 18;15:47. doi: 10.1186/s13024-020-00396-2

Fig. 2.

Fig. 2

GSK1482160 treatment reduced Tsg101+ immunoreactivity in P301S mouse brain. a. Tsg101 staining (green) in the hippocampus and cortex of mice ± GSK1482160 treatment, DG: dental gyrus; CA1 and CA3 of hippocampus; EC II: entorhinal cortex layer II. Scale bars = 200, 50, 20, 20 and 50 μm (left to right). b. Quantification of Tsg101 fluorescent intensity. *p < 0.05 and **p < 0.01 compared with WT + VEH group; #p < 0.05 and ##p < 0.01 compared with P301S + VEH group; n.s denotes no significance as determined by one-way ANOVA (alpha = 0.05) and Dunnett’s post-hoc. n = (6, 7, 7) mice for WT + VEH, P301S + VEH and P301S + GSK group. Graphs indicate mean ± s.e.m.